On May 18, 2016 Myriad Genetics, Inc. (NASDAQ:MYGN) reported it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting to be held June 3-7, 2016 in Chicago, Ill (Press release, Myriad Genetics, MAY 18, 2016, View Source [SID:1234512587]). Key podium presentations will highlight the safety and validity of the Myriad myRisk Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company’s presentations are available at: abstracts.asco.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re excited that the studies with myRisk Hereditary Cancer being presented at ASCO (Free ASCO Whitepaper) will advance the state-of-the-art of hereditary cancer testing," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "In particular, our new data provide additional evidence for expanding testing to a broader set of patients at risk for developing hereditary cancers, and for understanding the risks associated with mutations."
Myriad’s presentations are listed below. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.
myRisk Hereditary Cancer Presentations
Podium Presentations
Title: Yield of multiplex panel testing exceeds expert opinion and validated prediction models.
Presenter: Gregory Idos
Date: Sunday, June 5, 2016, 9:45 – 9:57 a.m.
Location: S404, Abstract:1509
Title: Ovarian cancer (OC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.
Presenter: Allison Kurian
Date: Monday, June 6, 2016, 10:09 – 10:21 a.m.
Location: E450ab, Abstract: 5510
Title: Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial.
Presenter: Allison Kurian
Date: Tuesday, June 7, 2016, 8:36 – 8:48 a.m.
Location: S102, Abstract:1503
Title: Prevalence of germline mutations in cancer risk genes among unselected colorectal cancer (CRC) patients (pts).
Presenter: Matthew Yurgelun
Date: Tuesday, June 7, 2016, 8:12 – 8:24 a.m.
Location: S102, Abstract:1501
Poster Presentations
Title: Genetic heterogeneity and survival among pancreatic adenocarcinoma (PDAC) patients with positive family history.
Presenter: Gloria Petersen
Date: Saturday, June 4, 2016, 8:00 – 11:30 a.m.
Location: Hall A, Abstract:4108, Poster Board 100
Title: Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene cancer panel.
Presenter: Bradford Coffee
Date: Monday, June 6, 2016, 8:00 – 11:30 a.m.
Location: Hall A, Abstract:1580, Poster Board 403
Poster Discussion Presentation
Title: Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.
Presenter: Michael Hall
Date: Monday, June 6, 2016, 8:00 — 11:30 a.m., Discussion 1:15 — 2:30 p.m.
Location: S404, Abstract:1512, Poster Board 335
myChoice HRD: Poster Presentation
Title: Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients.
Presenter: Jean Hansen
Date: Monday, June 6, 2016, 1:00 – 4:00 p.m.
Location: Hall A, Abstract: 5584, Poster Board 407
Prolaris Abstract Publication
Title: Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index.
Presenter: Neal Shore
Abstract: e16572
About Myriad myRisk Hereditary Cancer Testing
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms in an 850 step laboratory process to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: View Source
About myChoice HRD
Myriad’s myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers. It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents.